Inovio Pharmaceuticals In... (INO)
Inovio Pharmaceuticals Statistics
Share Statistics
Inovio Pharmaceuticals has 36.67M shares outstanding. The number of shares has increased by 41.51% in one year.
Shares Outstanding | 36.67M |
Shares Change (YoY) | 41.51% |
Shares Change (QoQ) | 1.57% |
Owned by Institutions (%) | 47.43% |
Shares Floating | 36.41M |
Failed to Deliver (FTD) Shares | 2.04K |
FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 3.5M, so 9.71% of the outstanding shares have been sold short.
Short Interest | 3.5M |
Short % of Shares Out | 9.71% |
Short % of Float | 9.79% |
Short Ratio (days to cover) | 11.22 |
Valuation Ratios
The PE ratio is -0.46 and the forward PE ratio is -0.71. Inovio Pharmaceuticals's PEG ratio is 0.01.
PE Ratio | -0.46 |
Forward PE | -0.71 |
PS Ratio | 228.26 |
Forward PS | 0.2 |
PB Ratio | 0 |
P/FCF Ratio | 0 |
PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Inovio Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.17.
Current Ratio | 2.77 |
Quick Ratio | 2.77 |
Debt / Equity | 0.17 |
Debt / EBITDA | -114.15 |
Debt / FCF | -0.11 |
Interest Coverage | -632.05 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $1.63K |
Profits Per Employee | $-800.4K |
Employee Count | 134 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.69% in the last 52 weeks. The beta is 0.92, so Inovio Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.92 |
52-Week Price Change | -86.69% |
50-Day Moving Average | 1.98 |
200-Day Moving Average | 5.05 |
Relative Strength Index (RSI) | 35.11 |
Average Volume (20 Days) | 853.76K |
Income Statement
In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.
Revenue | 217.76K |
Gross Profit | 217.76K |
Operating Income | -112.4M |
Net Income | -107.25M |
EBITDA | -103.95M |
EBIT | -107.08M |
Earnings Per Share (EPS) | -3.95 |
Balance Sheet
The company has 65.81B in cash and 11.87B in debt, giving a net cash position of 53.95B.
Cash & Cash Equivalents | 65.81B |
Total Debt | 11.87B |
Net Cash | 53.95B |
Retained Earnings | -1,730.2B |
Total Assets | 113.2M |
Working Capital | 62.5M |
Cash Flow
In the last 12 months, operating cash flow was -104.08B and capital expenditures 0, giving a free cash flow of -104.08B.
Operating Cash Flow | -104.08B |
Capital Expenditures | 0 |
Free Cash Flow | -104.08B |
FCF Per Share | -3831.86 |
Margins
Gross margin is 100%, with operating and profit margins of -51616.91% and -49254.27%.
Gross Margin | 100% |
Operating Margin | -51616.91% |
Pretax Margin | -49254269% |
Profit Margin | -49254.27% |
EBITDA Margin | -47735.19% |
EBIT Margin | -51616.91% |
FCF Margin | -47795033.43% |
Dividends & Yields
INO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for INO is $16.5, which is 937.7% higher than the current price. The consensus rating is "Buy".
Price Target | $16.5 |
Price Target Difference | 937.7% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Splits
The last stock split was on Jan 25, 2024. It was a backward split with a ratio of 1:12.
Last Split Date | Jan 25, 2024 |
Split Type | backward |
Split Ratio | 1:12 |
Scores
Altman Z-Score | -23.05 |
Piotroski F-Score | 1 |